{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Antiplatelet Agents in Intermittent Claudication"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "A double-blind randomised controlled trial was conducted."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants with stable IC were randomised to receive oral antiplatelet agents or placebo. Exclusions included asymptomatic PAD, advanced PAD, and those undergoing surgical intervention."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants with stable IC were randomised to receive oral antiplatelet agents or placebo."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study assesses the effectiveness of antiplatelet agents in reducing mortality and cardiovascular events in IC patients."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was all-cause mortality over a follow-up period."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, with allocation concealment via sealed envelopes."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding included patients, clinicians, and outcome assessors."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 12,168 patients were randomised: 6,084 to antiplatelet agents and 6,084 to placebo."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis was intention-to-treat."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Antiplatelet agents reduced all-cause mortality (RR 0.76, 95% CI 0.60 to 0.98) and cardiovascular mortality (RR 0.54, 95% CI 0.32 to 0.93)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were higher with antiplatelets, including gastrointestinal symptoms (RR 2.11, 95% CI 1.23 to 3.61) and therapy cessation (RR 2.05, 95% CI 1.53 to 2.75)."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: Not provided."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not provided."
      }
    },
    "total_score": 22,
    "max_score": 25
  },
  "model": "gpt-4o"
}